ClinicalTrials.gg
CompletedNCT07425392Updated Nov 13, 2026

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

A Phase 3 interventional study of 31-valent pneumococcal conjugate vaccine and PCV20 in Pneumococcal Disease, sponsored by Vaxcyte, Inc.. Completed at 30 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Vaxcyte, Inc. · Phase 3, Interventional, and Prevention

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
752
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Pneumococcal Infections with a site in United States — 6 open to participants now, 12 under way, 6 of them phase 3. Pneumococcal Infections · United States.

Enrollment
36th of 77
752 · median 605
Started
2026
with 8 others
Phase 3
39 of 83
4 open now
Registered
79th of 83
by date
Lead sponsor
5 of 83
Vaxcyte, Inc.

Among the 83 studies in Pneumococcal Infections with a site in United States, this one is the 36th largest by enrollment of the 77 interventional ones that give a count, is one of 9 that started in 2026, is one of 39 in phase 3, and was the 79th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

6 of the 83 studies in Pneumococcal Infections with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Pneumococcal Infections with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.

03

Conditions studied

  • Pneumococcal Disease

Keywords

  • Pneumonia
  • Pneumococcal Infection
  • 31-Valent PCV
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥50 years of age (inclusive) at the time of randomization into the study.
  • Previous receipt of a licensed pneumococcal vaccine or combination of licensed vaccines, with most recent vaccination ≥1 year prior to randomization; the exception is PCV21, which may have been received ≥6 months prior to randomization (confirmed).
  • Able and willing to complete the process.
  • Available for clinical follow-up through the last study visit.
  • In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator).
  • Willing to have blood samples collected and used for research purposes.
  • Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process.
  • Female participants of , defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable . Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method.
  • Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary).

Exclusion criteria

Exclusion Criteria:

  • Previous invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age.
  • Previous receipt of an pneumococcal vaccine at any age.
  • Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
  • Receipt of any within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1.
  • Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened).
  • Current diagnosis of , , or .
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination.
  • Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation.
  • Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency.
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or disorder requiring special precautions) resulting in bruising or bleeding difficulties with IM injections or blood draws.
  • Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study.
  • Is currently receiving or immune-modifying therapy, including systemic (this includes ≥3 months of prednisone equivalent from 5 to ≤10 mg/day and ≥2 weeks of prednisone equivalent >10 mg/day).
  • Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination

    • History of ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Any medical, psychiatric, or social condition that in the judgment of the Investigator is a to protocol participation or impairs a subject's ability to give .
  • Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
752 participants (actual)

Study arms

  • Experimental
    Cohort 1 (VAX-31): Prior PPSV23

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Biological: 31-valent pneumococcal conjugate vaccine

  • Active comparator
    Cohort 1 (PCV20): Prior PPSV23

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Biological: PCV20

  • Experimental
    Cohort 2 (VAX-31): Prior PCV20

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Biological: 31-valent pneumococcal conjugate vaccine

  • Active comparator
    Cohort 2 (PCV20): Prior PCV20

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Biological: PCV20

  • Experimental
    Cohort 3 (VAX-31): Other prior licensed pneumococcal vaccine or combination

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Biological: 31-valent pneumococcal conjugate vaccine

  • Active comparator
    Cohort 3 (PCV20): Other prior licensed pneumococcal vaccine or combination

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Biological: PCV20

Interventions

06

What researchers measure

Primary outcomes

  1. Serotype-specific OPA geometric mean titers (GMT)

    Time frame: 1 month after VAX-31 vaccination

  2. Serotype-specific OPA geometric mean fold rise (GMFR) from baseline

    Time frame: 1 month after VAX-31 vaccination

  3. Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)

    Time frame: up to 7 days after vaccination

  4. Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)

    Time frame: up to 7 days after vaccination

  5. Percentage of subjects reporting unsolicited AE

    Time frame: up to 31 days after vaccination

  6. Percentage of subjects reporting new onset of chronic illness (NOCI), medically attended AE (MAAE), and serious adverse events (SAE)

    Time frame: up to 6 months after vaccination

Secondary outcomes

  1. Serotype-specific IgG geometric mean concentration (GMC)

    Time frame: 1 month after VAX-31 vaccination

  2. Serotype-specific IgG geometric mean fold-rise (GMFR) from baseline

    Time frame: 1 month after VAX-31 vaccination

07

Study locations

30 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Oct 2026, 8 months.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2027 → Oct 2026 and completion Mar 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 20, 2026
StartActual
Feb 9, 2026
Primary completionActual
Oct 25, 2026was Mar 2027
CompletionActual
Oct 25, 2026was Mar 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Primary completion
Mar 2027→Oct 25, 2026 (actual)
Nov 13, 2026
Study completion
Mar 2027→Oct 25, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Active, not recruiting→Completed
    Primary completion Mar 2027→Oct 25, 2026 (now actual)
    Study completion Mar 2027→Oct 25, 2026 (now actual)
    + 3 other changes: index terms, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07425392
Lead sponsor
Vaxcyte, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 9, 2026
Primary completion
Oct 25, 2026
Completion
Oct 25, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion